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Abstract
Introduction Polypeptide fragments from cell surface recep-
tors when found in plasma may be indicators of receptor
regulation in disease conditions. It is known that subjects with
diabetes have significantly lower plasma concentrations of
adiponectin, a hormone released by adipose tissue, compared
with nondiabetic controls. This hormone interacts with cell
surface receptors in muscle (AdipoR1) and liver (AdipoR2).
Methods We analyzed the relative distribution of specific
fragments of AdipoR1 in healthy and diabetic individuals
using an immunoaffinity mass spectrometry approach. We
used antibodies raised against AdipoR1 immobilized on
pre-activated protein chip surfaces to determine the molec-
ular weights of bound polypeptide fragments using immu-
nomass spectrometry (immuno-MS).
Results Initially, immuno-MS analyses using a polyclonal
antibody revealed two peaks (m/z 3,902 and 7,812) in
plasma from normal, healthy individuals (n=5) that were
not present in the plasma of diabetics (n=5). To confirm the
detection of these fragments, a monoclonal antibody was
developed against the last 25 amino acids of the AdipoR1
C-terminal fragment (CTF). Using the immuno-MS meth-
od, the monoclonal antibody detected the AdipoR1 CTF
(m/z 3475) in all healthy controls (n=10), but did not detect
these fragments in the diabetic patients (n=10).
Discussion These preliminary observations suggest that the
plasma levels of this receptor fragment may serve as an
indicator of diabetic condition.
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Introduction
Studies have shown decreased concentrations of adiponec-
tin in plasma from obese individuals, and these findings
have also been inversely associated with insulin resistance
and a higher incidence of type 2 diabetes [1–10]. Adipo-
nectin is a 30-kD peptide hormone produced by adipose
tissue [11, 12]. This hormone has been shown to increase
insulin sensitivity by several mechanisms [13], including
inhibition of hepatic gluconeogenesis, activation of muscle to
increase glucose uptake and metabolism, and activation of
muscle and liver to increase fatty acid oxidation [14–16].
Adiponectin activates glucose metabolism through two
principal receptors: AdipoR1, predominately expressed in
skeletal muscle, and AdipoR2, predominately expressed in the
liver [12]. AdipoR1 and R2 consist of a seven-transmembrane
domain that is coupled to a G protein signaling pathway, but
unlike typical G protein receptors, the carboxyl terminus of
these adiponectin receptors is located on the extracellular side
of the membrane instead of on the intracellular side [12].
Reports indicate that AdipoR1 receptor expression, as
well as adiponectin hormone concentration, is reduced in
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diabetic conditions [17, 18]. Pugia postulated that the
turnover of the receptor could be measured by quantitating
the level of C-terminal fragments (CTFs) released into the
blood and went on to show by enzyme-linked immunosorbent
assay (ELISA) that levels of these fragments were signifi-
cantly altered in diabetes and cardiovascular disease patients
[19]. However, due to the limitations associated with the use
of ELISA, the specific CTFs could not be distinguished.
Considering the reduction in adiponectin and its receptor
in diabetes, the objective of the current study was to
establish whether the degraded fragments of the receptor
released in circulation of diabetics would be different from
nondiabetics. We therefore analyzed the relative distribution
of AdipoR1 receptor fragments in the plasma of healthy
and diabetic individuals. We report that a specific AdipoR1
CTF is present in the plasma of normal subjects but is
missing from the plasma of diabetic subjects.
Methods
Patient Samples
Heparinized plasma specimens from diabetic and normal
subjects were obtained from Siemens Diagnostics (Elkhart,
IN, USA). Sodium heparin plasma samples for normal
patients without diabetes, high cholesterol, hypertension or
metabolic syndrome, and body mass index (BMI) of <30
were collected in hospital and primary care settings
(Continental Services Group, Miami, FL, USA). Sodium
heparin plasma samples were collected for types I and II
diabetics enrolled in an in-house glucose meter study who
were routinely monitored by venous glucose and %HbA1c.
The institutional review board practices of our institutions
were followed, and analysts were blinded to all tests.
Specimens were aliquoted and maintained at −70°C until
analysis. Samples from five healthy and five diabetic
patients were used for the initial discovery work using
polyclonal antibody. Age, gender, and BMI demographics
matched between healthy and diabetic samples selected. For
the confirmation work using monoclonal antibody, additional
samples from five healthy and five diabetic patients were
added to the respective existing groups to yield n=10 for
each group.
Reagents: Peptide and Antibodies
The human AdipoR1 C-terminal peptide sequence (AdipoR1
357–375: N-L-Q-E-F-R-Y-G-L-E-G-G-C-T-D-D-T-L-L) was
synthesized with ≥90% purity by Phoenix Pharmaceuticals,
Inc. (Belmont, CA, USA). The lyophilized peptide (100 μg)
was resuspended with 60% acetonitrile in diH20 with 0.1%
trifluoroacetic acid and phosphate buffered saline (PBS;
pH 7.4). Final concentration of AdipoR1 peptide was
targeted to be 1 μg/μL (0.51 nmol/μL). Stock peptide was
aliquoted and maintained at −70°C. Peptide integrity check
using a NP20 chip type followed by mass spectrometric
analysis revealed mass of 2,144 Da that was comparable to
the calculated value of 2,126 Da. As mentioned by the
manufacturer, a 4,300-Da mass was also observed, represent-
ing a peptide dimer.
Anti-Human AdipoR1 (357–375)-NH2 polyclonal IgG
antibody was obtained from Phoenix Pharmaceuticals, Inc.
(Belmont, CA, USA). According to the manufacturer’s
instructions, 200 μg lyophilized antibody was resuspended
with PBS (pH 7.4) and diH2O to yield a final antibody
concentration of 1 μg/μL. Stock antibody was aliquoted and
maintained at −70°C. Antibody integrity check using a NP20
chip type followed by mass spectrometric analysis revealed a
pure antibody preparation, given a mass ≅ 143,800 Da. An
anti-Human AdipoR1 monoclonal IgG antibody was
obtained from Siemens Diagnostics (Elkhart, IN, USA).
Clone 444-1D12.1H7 was raised against the C-terminal
Adipo-R1 25 mer (H-F-Y-G-V-S-N-L-Q-E-F-R-Y-G-L-E-G-
G-C-T-D-D-T-L-L). Using diH20, stock antibody was diluted
to a final concentration of monoclonal Adipo-R1=1 μg/μL.
Stock antibody was aliquoted and maintained at −70°C.
Antibody integrity check using a NP20 chip type followed
by mass spectrometric analysis revealed a pure antibody
preparation, given a mass ≅ 147,600 Da. Anti-Human
Troponin I monoclonal IgG antibody (control) was obtained
from AbCam (Cambridge, MA, USA). Stock antibody was
aliquoted and maintained at −70°C. Stock antibody was
used at a final concentration equal to AdipoR1 antibodies
(1 μg/μL) as a nonspecific, IgG antibody control for
immunoaffinity capture experiments.
Immunomass Spectrometric Analysis
Polyclonal and monoclonal antibodies against epitopes of
the AdipoR1-CTF and the antibody control were immobi-
lized on pre-activated PS20 chip surfaces (Bio-Rad Labo-
ratories). Plasma samples from healthy and diabetic patients
as well as peptide controls were randomized in duplicate
across anti-AdipoR1/PS20 chips. The peptide standard and
cross-reactive protein/peptide species from plasma samples
were captured on the chip and their molecular weights were
determined by immunomass spectrometry.
Statistics
The selectively captured protein peaks were normalized.
Using the Biomarker Wizard Data Analysis Tool, an
unsupervised cluster analysis was performed. Signal/noise
ratio cutoffs of 10 (for polyclonal experiments) and 5 (for
monoclonal experiments) were used to select peaks with the
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greatest difference between healthy and diabetic patient
groups. Peak intensities were compared among the groups,
and p values were calculated using Biomarker Wizard.
Differences in peak intensities between the study groups
with p<0.05 were considered significant.
Results
Initial Discovery Using Polyclonal Anti-AdipoR1
Initial immunoaffinity capture studies using the polyclonal
antibody specific for the 19 C-terminal amino acids of
AdipoR1 revealed a number of captured peptides and
proteins (Fig. 1). From the peptide standard and the plasma
samples collected from healthy (n=5) and diabetic patients
(n=5), AdipoR1 and AdipoR1–ligand complexes from ∼2
to ∼33 kD were captured on the polyclonal AdipoR1/PS20
chips. Profile analysis from AdipoR1/PS20 chips revealed
15 cross-reactive peaks, five of which were of significant
interest at m/z of 3,902, 7,812, 14,636, 28,483, and 28,688,
respectively (Fig. 1). Cluster analysis suggested the 3,902
and 7,812 proteins were significantly increased in healthy
patients (p<0.0001), while the other three (14 and 28 kD)
proteins were increased in diabetics (p<0.01; Table 1).
Although not considered to be significantly different
between the control and diabetic groups, the other ten
peaks identified may represent different receptor–ligand
forms captured by the AdipoR1/PS20 chip. Subsequent
immunoaffinity capture analysis using the monoclonal
AdipoR1 antibody and more patient samples helped to
characterize the identity and significance of the captured,
cross-reactive species to AdipoR1.
Confirmation of Discovered Fragment by Monoclonal
Anti-AdipoR1 Antibody
As indicated above, the polyclonal antibody captured several
peaks, including the 3,902-Da fragment. As illustrated in
Fig. 3, this fragment is consistent with the last 35 amino
acids of AdipoR1 containing the transmembrane domain
with a calculated molecular weight of 3,824 Da. Therefore,
to assure that the captured CTF was in fact the extracellular
fragment of AdipoR1, a monoclonal antibody targeting only
the last 25 C-terminal amino acids (clone 444-1D12.1H7)
was generated and used for immunoaffinity capture studies
to confirm detection of these fragments in plasma from
healthy (n=10) and diabetic (n=10) subjects.
Using this monoclonal antibody to the 25 mer, two
specific C-terminal AdipoR1 fragments, 3,381 and 3,498 Da,
were captured on the monoclonal AdipoR1/PS20 chips.
Inherent to the clean capture of fragments with monoclonal
antibody, the other immunoreactive peaks captured using
polyclonal antibody were less evident. Both fragments
captured demonstrated significant differences between
healthy and diabetic subjects 3,381 Da (p<0.01) and
3,498 Da (p<0.05; Fig. 2). Notably, as observed in the
preliminary polyclonal capture experiment, both fragments
were consistently captured from plasma samples of healthy
patients. The captured corresponding masses surpass the total
mass of the 25 amino acid, extracellular CTF, and
approximate an AdipoR1 fragment 30–31 amino acids in
length (Fig. 3) with a calculated molecular weight of
3,475 Da for the 32-mer peptide. From this point, we











Fig. 1 Polyclonal AdipoR1-related immunoreactivity in healthy and
diabetic plasma. Polyclonal captured low molecular weight peaks
(3,902; 7,812) are present in healthy subjects, but absent in diabetics
(n=5). By contrast, polyclonal captured high molecular weight peaks
(14,636; 28,483; 28,688) are present in diabetics, but less abundant in
healthy subjects (n=5)
Table 1 Immunoaffinity capture of cross-reactive peaks with poly-
clonal AdipoR1








3,902 10.11 2.10 4.8 0.00067
7,812 5.11 1.21 4.2 0.00016
14,636 1.93 3.71 1.9 0.01261
28,483 5.37 7.99 1.5 0.04125
28,688 0.03429
m/z mass/charge ratio
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Discussion
It is well recognized that diabetes mellitus is a group of
metabolic diseases characterized by hyperglycemia result-
ing from defects in insulin production, secretion, action, or
combination thereof [20–22]. The American Diabetes
Association has systematically developed clinical practice
guidelines for the diagnosis and classification of diabetes.
Current recommendations for clinical laboratory testing
include fasting plasma glucose, glucose intolerance test,
and the oral glucose tolerance test. As evidenced by this
current clinical practice, the main criterion for making a
diagnosis of diabetes is an elevated glucose level. However,
recent evidence suggests that elevated blood glucose may
not be as strongly associated with diabetes as once believed
to be. A clinical study by Nichols and colleagues [23]
evaluated the risk of diabetes associated with normal fasting
glucose levels (less than 100 mg/dL) in over 46,578
patients. After nearly 7 years of follow-up, these subjects
developed type 2 diabetes at a rate of 1% per year. After
controlling for other risk factors, each milligrams per
deciliter rise in fasting blood glucose corresponded to an
increased diabetes risk by 6%, and subjects with glucose
levels of 95–99 mg/dL were 2.33 times more likely to
develop diabetes compared with those subjects with fasting
blood glucose levels of less than 85 mg/dL. Despite the
usefulness of clinical practice guidelines, these clinical
study findings would appear to stress a need to redefine the
criteria for diagnostic confirmation of diabetes and to seek
other candidate biomarkers that may be more useful in
predicting diabetes development.
Adiponectin and the interplay between its associated
receptor system (AdipoR1 and AdipoR2) have been
recognized as potential mechanisms for obesity, insulin
resistance, type 2 diabetes, and the metabolic syndrome.
This hormone-receptor system has been shown to play an
important role in energy homeostasis via its direct insulin-
sensitizing actions on tissues especially liver and skeletal
muscle [13–16]. In order to understand the role of
adiponectin and its receptor fragments in disease, we
characterized their cross-reactivities in plasma from healthy
and diabetic patients using immunomass spectrometry.
From a peptide standard as well as healthy and diseased
plasma samples, AdipoR1 fragments with molecular
weights of ∼3.5 kD were captured on the chip by
polyclonal and monoclonal AdipoR1 antibodies. Differen-
tial binding patterns between healthy and diabetic plasma
were identified, suggesting inherent differences in AdipoR1
fragments and/or AdipoR1-adiponectin (receptor–ligand)
complexes between these two groups. Ultimately, through
this study, we were able to identify a specific 31–32 amino
acid C-terminal AdipoR1 fragment in healthy patients that
was absent in diabetic individuals using a monoclonal
antibody targeted to capture the 25-mer Adipo-R1 CTF.
Altogether, these data confirmed that AdipoR1-related
fragments can be found in healthy control and diabetic
patients.
The two low molecular weight fragments (3,902 and
7,812) identified by the polyclonal AdipoR1 study likely
represent the CTF of AdipoR1, which may also include part
of the transmembrane domain. Additionally, given that the
extracellular, C-terminal domain contains a cysteine resi-
due, once this portion of R1 is shed or turned over, two
AdipoR1 C-terminal fragments could potentially dimerize.
This was also an observed phenomenon with the synthe-
sized C-terminal control AdipoR1 peptide used in this
study. Thus, the 7,812 fragment could potentially represent
the homodimerization of two C-terminal domains in healthy
individuals during normal receptor turnover. Alternatively,
the other higher molecular weight masses observed (14,636,
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Fig. 2 Monoclonal AdipoR1-related immunoreactivity in healthy and
diabetic plasma. Low molecular weight scan revealed significant differ-
ences between healthy subjects and diabetics. Representative scans (a) of
five of ten from each group are shown. Note: Scan noise is greater in
diabetic scans shown in a due to a fivefold increase in the peak intensity
scale. b Cluster analysis of monoclonal captured fragments from the
whole group of healthy (n=10) and diabetic (n=10) patients indicate
that 3,381 and 3,498 peaks are significantly associated with healthy
individuals and absent or less abundant in diabetics
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associated with the presence of a diabetic state. Further testing
revealed that the later three masses corresponded to adipo-
nectin in the globular (gAdpn) and full-length (fAdpn) forms
binding as cross-reactive species to the polyclonal. To help
rule out CTF-mediated immunoaffinity capture of adiponectin
by the polyclonal antibody in diabetics, further capture work
was performed after co-incubation of adiponectin (gAdpn and
fAdpn forms) and purified CTF peptide. Notably, these co-
incubation experiments performed indicated that a synthe-
sized AdipoR1 fragment did not bind to adiponectin in either
form and the repeat immunoaffinity capture using a polyclonal
antibody for adiponectin confirmed these findings (data not
shown).
The subsequent monoclonal work identified a specific
31–32 amino acid (3,381 and 3,498 Da) AdipoR1 CTF in
healthy patients that was absent in diabetic individuals. A
potential explanation of differences in fragmentation pat-
terns between these two study groups is the lack of
multimer adiponectin during the insulin resistant diabetic
state and a high rate of receptor turnover in insulin-
responsive, healthy individuals.
As demonstrated, immunoaffinity capture followed by
mass spectrometric determination of the molecular weights
of the captured peptides and proteins can be a powerful
biomarker discovery tool. In this study, since the molecular
weights of a number of the discovered species were less
than 10 kD, Western blot analysis would not have resolved
the discovered peaks. Likewise, due to the many different
cross-reactive forms being present in each sample, using
ELISA, the observed differences in AdipoR1 cross-
reactivity between healthy and diabetic plasma may have
been masked. Therefore, we conclude that immunoaffinity
mass spectrometry is a powerful and useful tool to
determine antibody specificity and, more specifically, the
molecular weight and fundamental identity of ligands or
cross-reactive ligands. Further research and biomarker
discovery studies using proteomic tools such as immunoaf-
finity capture are necessary to continue to help define and
understand the potential role of adipokines and AdipoR1-
related fragments in healthy and disease states.
Potentially cell surface receptor fragments released in vivo
can serve as novel sources of biomarkers indicative of receptor
regulation in disease conditions. In fact, there have been
several published studies in which fragments of transmem-
brane proteins have been generated via ectodomain cleavage.
For instance, a 100-kD fragment of the N-terminal ectodo-
main of amyloid precursor protein is known to be generated
by α-secretase, which cleaves the protein at a site that
precludes the formation of the amyloid plaque-forming βA4
peptide [24, 25]. As reviewed by Fortini [26], binding of
ligands of the Delta/Serrate/Jagged family to the Notch
receptor triggers the cleavage of the extracellular domain of
Notch by tumor necrosis factor-α-converting enzyme/a
disintegrin and metalloprotease-17 (TACE/ADAM17). The
N-terminal ectodomain of the ErbB-4 receptor can also be
cleaved by TACE/ADAM17 to yield an m80 fragment,
which has been found to be associated with the full-length
ErbB-2 receptor [27]. More recently, a study by Szklarczyk
and colleagues [28] demonstrated that the zinc-dependent
matrix metalloproteinase-7 can cleave the NR1 subunit of the
N-methyl-D-aspartate (NMDA) receptor at a site within the
extracellular ligand binding domain, leading to impairment
of NMDA-stimulated calcium flux in cortical neurons
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Fig. 3 AdipoR1 receptor. The
AdipoR1 receptor is an atypical
seven-transmembrane domain,
G protein-coupled receptor. As
shown, the AdipoR1 receptor is
unique in that the C-terminal
end is located on the extracellu-
lar side of the membrane and
N-terminal on the intracellular
side. AdipoR1 C-terminal frag-
ments of interest are highlighted
including the 19-, 25-, 32-, and
35-amino acid fragments: 19-aa
fragment represents target for
polyclonal antibody, 25-aa frag-
ment represents the target for the
monoclonal antibody, 32-aa
fragment represents the clinical
fragment captured by the mono-
clonal AdipoR1 immunoaffinity,
and 35-aa fragment represents
the polyclonal AdipoR1 immu-
noaffinity captured fragment
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stable N-terminal fragments of the NR2 subunit of the
NMDA receptor have been generated via proteolytic
cleavage [29, 30], and autoantibodies against these fragments
have been detected in the blood of transient ischemic attack
and stroke patients [31]. The detection of these autoanti-
bodies in human serum indicates that these N-terminal
fragments can cross the blood–brain barrier and enter the
bloodstream [31].
Furthermore, investigating cell responses and differences
in signaling pathways have led to a better understanding of
the role of the adiponectin–receptor axis in disease.
Stimulation of adiponectin receptors enhances glucose
uptake and fatty acid oxidation through activation of 5′-
adenosine monophosphate-activated protein kinase and
parallel phosphorylation of acetyl coenzyme A carboxylase
[15]. Binding of adiponectin to its receptors has been
shown to activate peroxisome proliferator-activated recep-
tor α and subsequent stimulation of fatty acid oxidation and
reduction of triglyceride content in muscle and liver [12,
14]. The adiponectin receptors respond differently to the
various forms of adiponectin, which are primarily either full
length or globular (i.e., fAdpn or gAdpn) [32]. Adiponectin
has been shown to regulate inflammation and protect against
atherogenesis by antagonizing the pro-inflammatory effects
of tumor necrosis factor-α [14, 33–37]. Due to C1q-like,
collagenous domains, fAdpn monomers can aggregate into
multimers of low, medium, and high (HMW) molecular
weight forms, with the HMW form accounting for half of
total adiponectin in normal individuals [32, 38–40]. A
proteolytic cleavage product of adiponectin is known as
gAdpn. AdipoR2 only reacts to the fAdpn form while
AdipoR1 is more responsive to the gAdpn form [40].
As reviewed by Tilg and Moschen [11], expansion of
adipose tissue during weight gain can lead to release of pro-
inflammatory cytokines and recruitment of macrophages,
resulting in a low-grade inflammatory state. An increase of
these pro-inflammatory mediators is also accompanied with
a decline in the release of adiponectin from adipose tissue.
In conjunction with the observed decrease in adiponectin
levels, obesity may either directly lead to decreased
expression of AdipoR, or it may indirectly reduce expres-
sion of these receptors via producing hyperinsulinemia
[41]. A study of fasted and re-fed ob/ob mice [17] revealed
that expression of AdipoR1 and Adipo R2 in skeletal
muscle and liver, respectively, were increased during
fasting, but were decreased to their original fed state levels
during refeeding. Furthermore, when hypoinsulinemia/
hyperglycemia was induced by streptozotocin, AdipoR1
and R2 mRNA expression were increased in these mice,
and notably, after treatment with insulin, expression levels
of both receptors were reduced to nearly the original values.
Under conditions of hyperinsulinemia and hyperglycemia,
an in vitro study [42] of rat skeletal muscle cells
demonstrated a 50% decrease in AdipoR1 mRNA levels
and R1 expression, which correlated with reduced meta-
bolic effects of gAdpn in these skeletal muscle cells. In
addition, hyperinsulinemia alone induced a threefold
increase in AdipoR2 expression and enhanced the meta-
bolic effects of fAdpn in these cells. This alteration in
AdipoR expression and the variation in response to the
gAdpn and fAdpn forms are the basis for the proposed
adiponectin resistance in type 2 diabetes, and this type of
resistance can lead to the creation of a vicious cycle that
exacerbates the development of diabetes [41].
In our preliminary experiments using Western blotting
and an ELISA polyclonal antibody method, we detected
fragments of the extracellular C terminus of AdipoR1 in
human plasma and urine [19]. However, due to limitations
associated with the use of a polyclonal antibody, the
specific fragments could not be distinguished. To confirm
the identity and characterize the potential AdipoR1’s
specific fragments in plasma, we used a novel approach
by combining mass spectrometry and monoclonal antibody
cross-reactivity for rapid characterization of plasma proteins
in pursuit of discovery of new biomarkers [43]. This
technique allows for a highly sensitive approach to study
antibody–ligand interactions, which we have previously
utilized to study the interaction of various forms of troponin
I to its antibodies [44]. Having the monoclonal antibody
against AdipoR1 CTF will allow the development of
specific immunoassays to be used in assessing the utility
of this putative biomarker for diabetes.
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